BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10606897)

  • 1. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
    Lazzarino M; Orlandi E; Baldanti F; Furione M; Pagnucco G; Astori C; Arcaini L; Viglio A; Paulli M; Gerna G; Bernasconi C
    Br J Haematol; 1999 Dec; 107(4):877-82. PubMed ID: 10606897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
    Lazzarino M; Orlandi E; Montillo M; Tedeschi A; Pagnucco G; Astori C; Corso A; Brusamolino E; Simoncini L; Morra E; Bernasconi C
    Ann Oncol; 1999 Jan; 10(1):59-64. PubMed ID: 10076723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
    Abruzzo LV; Rosales CM; Medeiros LJ; Vega F; Luthra R; Manning JT; Keating MJ; Jones D
    Am J Surg Pathol; 2002 May; 26(5):630-6. PubMed ID: 11979093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
    Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
    Rao R; Shammo JM; Enschede SH; Porter C; Adler SS; Venugopal P; Gregory SA
    Clin Lymphoma; 2005 Jun; 6(1):26-30. PubMed ID: 15989703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.
    Shields DJ; Byrd JC; Abbondanzo SL; Lichy JH; Diehl LF; Aguilera NI
    Mod Pathol; 1997 Nov; 10(11):1151-9. PubMed ID: 9388067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas.
    Fenchel K; Bergmann L; Wijermans P; Engert A; Pralle H; Mitrou PS; Diehl V; Hoelzer D
    Leuk Lymphoma; 1995 Aug; 18(5-6):485-92. PubMed ID: 8528057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
    O'Brien ME; Matutes E; Cunningham D; Hill M; Emmett E; Ellis PA; Milan S; Hickish T; Mercieca J; Catovsky D
    Leuk Lymphoma; 1994; 14 Suppl 2():17-23. PubMed ID: 7881347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
    Tsimberidou AM; O'Brien SM; Cortes JE; Faderl S; Andreeff M; Kantarjian HM; Keating MJ; Giles FJ
    Leuk Lymphoma; 2002 Apr; 43(4):767-72. PubMed ID: 12153163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
    Bosch F; Ferrer A; López-Guillermo A; Giné E; Bellosillo B; Villamor N; Colomer D; Cobo F; Perales M; Esteve J; Altés A; Besalduch J; Ribera JM; Montserrat E;
    Br J Haematol; 2002 Dec; 119(4):976-84. PubMed ID: 12472576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Bendandi M; Magagnoli M; Rondelli D; de Vivo A; Benni M; Zamagni E; Cavo M; Tura S
    Eur J Haematol; 1997 Aug; 59(2):82-8. PubMed ID: 9293855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
    Schiavone EM; De Simone M; Palmieri S; Annunziata M; Pocali B; Copia C; D'Amico MR; Vecchio LD; Ferrara F
    Eur J Haematol; 2003 Jul; 71(1):23-8. PubMed ID: 12801295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
    Lossos IS; Paltiel O; Polliack A
    Leuk Lymphoma; 1999 Mar; 33(1-2):155-60. PubMed ID: 10194133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
    Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H
    Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
    Hallek M; Schmitt B; Wilhelm M; Busch R; Kröber A; Fostitsch HP; Sezer O; Herold M; Knauf W; Wendtner CM; Kuse R; Freund M; Franke A; Schriever F; Nerl C; Döhner H; Thiel E; Hiddemann W; Brittinger G; Emmerich B;
    Br J Haematol; 2001 Aug; 114(2):342-8. PubMed ID: 11529853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
    Kasamon YL; Flinn IW; Grever MR; Diehl LF; Garrett-Mayer E; Goodman SN; Lucas MS; Byrd JC
    Clin Cancer Res; 2005 Dec; 11(23):8413-7. PubMed ID: 16322303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
    Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
    Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.